Electronic Resource
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study.
| العنوان: | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. |
|---|---|
| المؤلفون: | Howard J., Parker S., Welby S., Page F., Corker M., Wykes R., Goss C., Whitney S., Oates J., Soulis E., Hoque M., Gebbie C., Tebbutt N.C., Wilson K., Gebski V.J., Cummins M.M., Zannino D., Van Hazel G.A., Robinson B., Broad A., Ganju V., Ackland S.P., Forgeson G., Cunningham D., Saunders M.P., Stockler M.R., Chua Y., Zalcberg J.R., Simes R.J., Price T.J., Price T., Coates A., O'Connell D., Brown C., Hague W., France A., Hicks S., James R., Masson R., O'Connell R., Pike R., Shoulder J., Stevens L., Tunney V., Vachan B., Wong N., Ackland S., Moylan E., Strickland A., Abdi E., Ransom D., Lowenthal R., Marx G., Nayagam S.S., Shannon J., Goldstein D., Karapetis C., Blum R., Eek R., Ward R., Pavlakis N., Wilcken N., Burns I., Wyld D., Underhill C., Claringbold P., Liauw W., Clingan P., Jefford M., Horvath L., McKendrick J., Chong G., Boyce A., Cassidy J., Kirsten F., Clarke S., Guo Y., Innes-Rowe J., Smith A., Williams J., Tournier E., Maliepaard S., Vitullo E., Humm G., Nguyen V., Midolo P., Chorlton C., McDonald L., Oliver L., Sjursen A.-M., Inglis C., Marafioti T., McCourt J., Richards A., Provis A., Rundle A., Whatman A., Emmett L., Raymond B., Byrne S., Withers E., Campbell J., Hodgkins C., Szwajcer M. |
| بيانات النشر: | American Society of Clinical Oncology (E-mail: jcoservice@asco.org) United States 2011-03-01 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial. Patients and Methods: Overall, 471 patients in Australia, New Zealand, and the United Kingdom with previously untreated, unresectable mCRC were randomly assigned to the following: capecitabine; capecitabine plus bevacizumab (CB); or capecitabine, bevacizumab, and mitomycin (CBM). We compared CB with capecitabine and CBM with capecitabine for progression-free survival (PFS). Secondary end points included overall survival (OS), toxicity, response rate (RR), and quality of life (QOL). Result(s): Median PFS was 5.7 months for capecitabine, 8.5 months for CB, and 8.4 months for CBM (capecitabine v CB: hazard ratio [HR], 0.63; 95% CI, 0.50 to 0.79; P < .001; C v CBM: HR, 0.59; 95% CI, 0.47 to 0.75; P < .001). After a median follow-up of 31 months, median OS was 18.9 months for capecitabine and was 16.4 months for CBM; these data were not significantly different. Toxicity rates were acceptable, and all treatment regimens well tolerated. Bevacizumab toxicities were similar to those in previous studies. Measures of overall QOL were similar in all groups. Conclusion(s): Adding bevacizumab to capecitabine, with or without mitomycin, significantly improves PFS without major additional toxicity or impairment of QOL. Copyright © 2010 by American Society of Clinical Oncology. |
| مصطلحات الفهرس: | colorectal cancer/dt [Drug Therapy], diarrhea/si [Side Effect], fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, hand foot syndrome/si [Side Effect], hemolytic uremic syndrome/si [Side Effect], human, hypertension/si [Side Effect], infection/si [Side Effect], intestine perforation/si [Side Effect], major clinical study, male, metastasis/dt [Drug Therapy], multicenter study, nausea/si [Side Effect], neutropenia/si [Side Effect], New Zealand, overall survival, phase 3 clinical trial, priority journal, progression free survival, proteinuria/si [Side Effect], quality of life, randomized controlled trial, side effect/si [Side Effect], stomatitis/si [Side Effect], thrombocytopenia/si [Side Effect], thromboembolism/si [Side Effect], treatment response, United Kingdom, vein embolism/si [Side Effect], vein thrombosis/si [Side Effect], vomiting/si [Side Effect], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/cb [Drug Combination], bevacizumab/cm [Drug Comparison], bevacizumab/dt [Drug Therapy], capecitabine/ae [Adverse Drug Reaction], capecitabine/ct [Clinical Trial], capecitabine/cb [Drug Combination], capecitabine/cm [Drug Comparison], capecitabine/dt [Drug Therapy], mitomycin/ae [Adverse Drug Reaction], Australia, mitomycin/cb [Drug Combination], mitomycin/cm [Drug Comparison], mitomycin/dt [Drug Therapy], bleeding/si [Side Effect], mitomycin/ct [Clinical Trial], adult, aged, article, Article |
| URL: | Journal of Clinical Oncology LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2020 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/30424 Journal of Clinical Oncology. 28 (11) (pp 3191-3198), 2010. Date of Publication: 01 Jul 2010. 0732-183X https://repository.monashhealth.org/monashhealthjspui/handle/1/30424 20516443 [http://www.ncbi.nlm.nih.gov/pubmed/?term=20516443] 361298315 (Wilson, Gebski, Cummins, Zannino, Van Hazel, Robinson, Broad, Ganju, Ackland, Forgeson, Cunningham, Saunders, Stockler, Chua, Zalcberg, Simes, Price) Peter MacCallum Cancer Centre; Frankston Hospital, Melbourne; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney; Sir Charles Gairdner Hospital, Perth; Geelong Hospital, Geelong; Canberra Hospital, Canberra; Queen Elizabeth Hospital, Adelaide; Calvary Mater Newcastle Hospital, Newcastle, Australia; Royal Marsden Hospital, London; Christie Hospital, Manchester, United Kingdom; Christchurch Hospital, Christchurch; and Palmerston North Hospital, Palmerston North, New Zealand. (Tebbutt, Guo) Austin Health, Melbourne, Australia (Price, Williams) Queen Elizabeth Hospital, Adelaide, Australia (Wilson, Gebski, Simes) NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia (Van Hazel, Innes-Rowe) Sir Charles Gairdner Hospital, Australia (Robinson, Smith) Christchurch Hospital, New Zealand (Broad, Tournier) Geelong Hospital, Australia (Ganju, Maliepaard) Frankston Hospital, Australia (Ackland, Vitullo) Calvary Mater Newcastle Hospital, Australia (Forgeson, Humm) Palmerston North Hospital, Australia (Moylan, Nguyen) Liverpool Hospital, Australia (Strickland, Midolo) Monash Medical Centre, Australia (Abdi, Chorlton) Tweed Hospital, Australia (Ransom, McDonald) St John of God Hospital, Subiaco, Australia (Lowenthal, Oliver) Royal Hobart Hospital, Australia (Saunders, Sjursen) Christie Hospital, Australia (Marx, Inglis) Sydney Haematology and Oncology Clinic, Australia (Nayagam, Marafioti) Royal Adelaide Hospital, Australia (Shannon, McCourt) Nepean Cancer Care Centre, Australia (Goldstein, Howard) Prince of Wales Hospital, Australia (Karapetis, Richards) Flinders Medical Centre, Australia (Blum, Rundle) Bendigo Hospital, Australia (Eek, Whatman) Campbelltown Hospital, Australia (Ward) St Vincent's Hospital, Sydney, Australia (Pavlakis, Raymond) Royal North Shore Hospital Tebbutt N.C.; niall.tebbutt@ludwig.edu.au 1305112874 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305112874 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |